OBJECTIVE： To provide evidence-based evidence for health policy decision and clinical practice by systematically evaluating efficacy， safety， economical efficiency and applicability of Bromfenac （BRO） sodium ophthalmic solution in the treatment of ocular inflammation. METHODS： Retrieved from PubMed， Embase，The Cochrane Library，CNKI，Wanfang Data，VIP and health technology assessment （HTA） organization websites， HTA report， systematic reviews （SR）， randomized controlled trials （RCT） and pharmacoeconomic studies about inclusion of BRO sodium ophthalmic solution in contrast with placebo， steroids， and the other NSAIDs for ocular inflammation were included. The data extraction and quality evaluation were conducted by using Cochrane systematic evaluator Rev Man 5.1.0. Meta-analysis was conducted in RCT documents， and Rev Man 5.3 was used for Meta analysis，while other studies were analyzed with descriptive analysis qualitatively. Its economy was analyzed by minimum cost analysis method. RESULTS： Totally 2 SR （9 528 patients） and 39 RCTs （6 848 eyes） were included. No HTA report and pharmacoeconomic study was found. Results of systematic reviews showed that BRO ophthalmic solutioncould effectively relieve ocular inflammation， ocular pain and reduce the incidence of relative adverse. Results of Meta-analysis showed that compared with placebo， anti-inflammation [RR＝2.10，95％CI（1.78，2.50），P＜0.001]， analgesia [RR＝2.21，95％CI（1.04，4.72），P＝0.04] and intra-ocular pressure reduction [MD＝－1.06，95％CI（－2.06，－0.05），P＝0.04] of BRO sodium ophthalmic solution were better； there was no statistical significance in the incidence of total adverse events or severe adverse events （P＞0.05）. Compared with steroids， BRO sodium ophthalmic solution showed similar effect on ocular inflammation， decrease of intra-ocular pressure or the improvement of vision （P＞0.05）. There was no statistical significance in the ocular inflammation， pain decrease of intra-ocular pressure or the improvement of vision between NSAIDs and BRO sodium ophthalmic solution （P＞0.05）. Compared with loteprednol eye drops， BRO sodium ophthalmic solution showed advantages economically. Twice daily used BRO sodium ophthalmic solution improved compliance of subjects than other eye drops. CONCLUSIONS： BRO sodium ophthalmic solution has favorable efficacy， safety and applicability in the treatment of ocular inflammation. Compared with loteprednol eye drops， it shows advantages economically.